General Information |
| Summary |
This is a safety follow-up study. Patients enrolled in B4711001 will be followed for a further 4 years with regular visits to assess safety. |
| Clinical trials phase |
Long term follow up |
| Start date (estimated) |
2023-05-21 |
| End date (estimated) |
2033-05-30 |
| Clinical feature |
| Label |
age related macular degeneration |
| Link |
http://purl.obolibrary.org/obo/DOID_10871 |
| Description |
A degeneration of macula and posterior pole that is characterized by a loss of vision in the center of the visual field (the macula) resulting from damage to the retina and resulting in blurring of the sharp central vision.; OMIM mapping confirmed by DO. [SN]. |
|
Administrative Information |
| NCT number |
NCT03102138 |
| ICTRP weblink |
https://trialsearch.who.int/Trial2.aspx?TrialID=NCT03102138 |
| EudraCT number |
2015-002267-42 |
| Other study identifiers |
|
| Source weblink |
https://clinicaltrials.gov/ct2/show/NCT03102138 |
| Study sites |
|
| Public contact |
| Email |
ClinicalTrials.gov_Inquiries@pfizer.com |
| Public email |
moorfields.resadmin@nhs.net |
| First name |
Tania |
| Last name |
West |
| Phone |
+44 20725334112036 |
| Country |
|
|
| Sponsors |
Pfizer
|
Cells |
| Source pluripotent stem cell lines |
|
| Which differentiated cell type is used |
| Label |
retinal pigment epithelial cell |
| Link |
http://purl.obolibrary.org/obo/CL_0002586 |
| Description |
An epithelial cell of the retinal pigmented epithelium. |
|
Recruitment |
| Recruitment Status |
Not yet recruiting |
| Estimated number of participants |
10 |
| Contact institutions/departments |
|
